FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Recent health updates highlight the FDA's approval of Lantheus' new prostate cancer imaging agent to enhance production ...

The FDA approved a new Lantheus prostate cancer imaging agent. South Carolina's measles cases rise. Medtronic's MiniMed shares drop in Nasdaq debut. A French probe exonerates Nestle in a baby death ...

Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...

New AI tool from UC San Diego and collaborators precisely maps the urethra on MRI to make prostate cancer radiation safer and reduce urinary side effects. Running on SDSC’s Expanse supercomputer, the ...

The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.

Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided ...

NFL Icons Coach Bruce Arians, Rob Gronkowski, George Kittle and more partner with Novartis to prioritize early prostate cancer detection One in eight men will face prostate cancer 1, yet fear and ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...